Tareq Abadl: Not Every Rh-Positive or Rh-Negative Result is That Simple
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“Not every ‘Rh-Positive’ or ‘Rh-Negative’ result is that simple!
Most people think RhD typing is a clear yes or no — but in transfusion medicine, it’s not always that straightforward.
Some individuals have what’s called a weak D or other RHD variants.
This means the D antigen is present, but expressed at very low levels, structurally altered or reacts inconsistently in routine testing.
Because of this, standard serologic typing may give uncertain or misleading results.
Why does this matter?
In blood banking, especially during pregnancy, this distinction is critical.
The American Red Cross notes that weak or altered D expression can produce a serologic weak D phenotype.
The AABB recommends molecular (genotyping) testing when RhD results are unclear.
Why? Because management decisions can change.
- Weak D types 1, 2, and 3 – can be safely treated as RhD-positive.
- Other variants (like partial D) – may still form anti-D – managed as RhD-negative
Key clinical impact this directly affects:
- Rh immune globulin (RhIg) use.
- Blood transfusion selection.
- Risk of alloimmunization.
Without genotyping, patients may: receive unnecessary RhIg or be given Rh-negative blood unnecessarily (a limited resource).
Even donor testing is more detailed than people expect: The Canadian Blood Services confirms that first-time donors typed as Rh-negative are often retested for weak D to ensure accurate classification.
Newer Insight (Important): Recent practice is shifting toward
- Routine RHD genotyping in pregnant patients with weak D.
- Better standardization of interpretation across labs.
- Reducing variation between hospitals in RhIg decisions.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause